ERBB2 and breast cancer: Regarding Trastuzumab, it is a humanized monoclonal antibody obtained by genetic engineering technologies, able to inhibit the activation of human epidermal growth factor receptor 2 (HER2)/neu, a glycoprotein receptor with tyrosine kinase activity, which, when altered, promotes breast cancer cells growth.